An updated systematic review of the impact of medications with anticholinergic activity on cognitive function and mortality

Ian Maidment, Wei-Yee Chan, Nelson Bua, Phyo Myint, Noll Campbell, Malaz Boustani, Chun Shing Kwok, Chris Fox

Research output: Contribution to journalAbstract


An estimated 18% of older (≥ 65) adults suffer from mild cognitive impairment (MCI). More than half will progress to dementia within 5 years. Primary prevention may be by recognition of the true burden of anticholinergic drugs on cognition and avoidance wherever possible. This project aimed to systematically review the literature to update a widely used scale that assesses anti-cholinergic burden (ACB scale) and establish the impact of drugs with anticholinergic properties on cognitive function in patients over the age of 18 without a diagnosis of dementia.
Original languageEnglish
Pages (from-to)P774
Number of pages1
JournalAlzheimer's and Dementia
Issue number4
Publication statusPublished - 2013


Cite this